These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 33201054)

  • 1. Clinical and Histological Characterization of Toxic Keratopathy From Depatuxizumab Mafodotin (ABT-414), an Antibody-Drug Conjugate.
    Lee BA; Lee MS; Maltry AC; Hou JH
    Cornea; 2021 Sep; 40(9):1197-1200. PubMed ID: 33201054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Histological Characterization of Toxic Keratopathy From Depatuxizumab Mafodotin (ABT-414), an Antibody-Drug Conjugate: [RETRACTED].
    Lee BA; Lee MS; Maltry AC; Hou JH
    Cornea; 2018 May; ():. PubMed ID: 29794826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.
    Clement PMJ; Dirven L; Eoli M; Sepulveda-Sanchez JM; Walenkamp AME; Frenel JS; Franceschi E; Weller M; Chinot O; De Vos FYFL; Whenham N; Sanghera P; Looman J; Kundu MG; Peter de Geus J; Nuyens S; Spruyt M; Gorlia T; Coens C; Golfinopoulos V; Reijneveld JC; van den Bent MJ
    Eur J Cancer; 2021 Apr; 147():1-12. PubMed ID: 33601293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin.
    Vize CJ; Kim SK; Matthews T; Macsai M; Merrell R; Hsu S; Kundu MG; Yoon J; Kennedy E; Pai M; Bain E; Lassman AB; Moazami G
    Ophthalmic Res; 2023; 66(1):1030-1043. PubMed ID: 37257422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
    van den Bent M; Gan HK; Lassman AB; Kumthekar P; Merrell R; Butowski N; Lwin Z; Mikkelsen T; Nabors LB; Papadopoulos KP; Penas-Prado M; Simes J; Wheeler H; Walbert T; Scott AM; Gomez E; Lee HJ; Roberts-Rapp L; Xiong H; Bain E; Ansell PJ; Holen KD; Maag D; Reardon DA
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1209-1217. PubMed ID: 29075855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
    Goss GD; Vokes EE; Gordon MS; Gandhi L; Papadopoulos KP; Rasco DW; Fischer JS; Chu KL; Ames WW; Mittapalli RK; Lee HJ; Zeng J; Roberts-Rapp LA; Loberg LI; Ansell PJ; Reilly EB; Ocampo CJ; Holen KD; Tolcher AW
    Cancer; 2018 May; 124(10):2174-2183. PubMed ID: 29533458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization and Potential Mitigation of Corneal Effects in Nonclinical Toxicology Studies in Animals Administered Depatuxizumab Mafodotin.
    Loberg LI; Henriques TA; Johnson JK; Miller PE; Ralston SL
    J Ocul Pharmacol Ther; 2022 Sep; 38(7):471-480. PubMed ID: 35537481
    [No Abstract]   [Full Text] [Related]  

  • 8. An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti-EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFR.
    Mittapalli RK; Stodtmann S; Friedel A; Menon RM; Bain E; Mensing S; Xiong H
    J Clin Pharmacol; 2019 Sep; 59(9):1225-1235. PubMed ID: 30990907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFR
    von Achenbach C; Silginer M; Blot V; Weiss WA; Weller M
    Mol Cancer Ther; 2020 Jun; 19(6):1328-1339. PubMed ID: 32371586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corneal side effects induced by EGFR-inhibitor antibody-drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy study.
    Parrozzani R; Lombardi G; Midena E; Leonardi F; Londei D; Padovan M; Caccese M; Marchione G; Bini S; Zagonel V; Frizziero L
    Ther Adv Med Oncol; 2020; 12():1758835920907543. PubMed ID: 32550861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.
    Phillips AC; Boghaert ER; Vaidya KS; Falls HD; Mitten MJ; DeVries PJ; Benatuil L; Hsieh CM; Meulbroek JA; Panchal SC; Buchanan FG; Durbin KR; Voorbach MJ; Reuter DR; Mudd SR; Loberg LI; Ralston SL; Cao D; Gan HK; Scott AM; Reilly EB
    Mol Cancer Ther; 2018 Apr; 17(4):795-805. PubMed ID: 29483208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors.
    Shin E; Lim DH; Han J; Nam DH; Park K; Ahn MJ; Kang WK; Lee J; Ahn JS; Lee SH; Sun JM; Jung HA; Chung TY
    BMC Ophthalmol; 2020 Jan; 20(1):19. PubMed ID: 31918686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and Histological Characterization of Toxic Keratopathy From Depatuxizumab Mafodotin (ABT-414), an Antibody-Drug Conjugate: Retraction.
    Cornea; 2018 Nov; 37(11):e55. PubMed ID: 30102618
    [No Abstract]   [Full Text] [Related]  

  • 14. Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report.
    Marquant K; Quinquenel A; Arndt C; Denoyer A
    J Hematol Oncol; 2021 Oct; 14(1):159. PubMed ID: 34602074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocular surface toxicity of depatuxizumab mafoditin (ABT-414): case reports.
    Rocha-de-Lossada C; Linero CA; Ortega ÁS; Calvo-de-Mora MR; Rachwani R; Borroni D; Alba E; Orgaz MB; Romano V
    Arq Bras Oftalmol; 2021; 85(4):411-414. PubMed ID: 34586240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visualization of Keratopathy Associated With the Antibody-Drug Conjugate Belantamab Mafodotin Using Infrared Imaging in Patients With Multiple Myeloma.
    Gallin V; Nölle B; Schub N; Roider J
    Cornea; 2024 Jun; ():. PubMed ID: 38900711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel agent for myeloma causing toxic keratopathy, belantamab mafodotin: a case report and literature review.
    Kurt RA; Gören D; Karadeniz S; Arat M; Sahin A
    Arq Bras Oftalmol; 2022 Nov; ():. PubMed ID: 36350901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
    Van Den Bent M; Eoli M; Sepulveda JM; Smits M; Walenkamp A; Frenel JS; Franceschi E; Clement PM; Chinot O; De Vos F; Whenham N; Sanghera P; Weller M; Dubbink HJ; French P; Looman J; Dey J; Krause S; Ansell P; Nuyens S; Spruyt M; Brilhante J; Coens C; Gorlia T; Golfinopoulos V
    Neuro Oncol; 2020 May; 22(5):684-693. PubMed ID: 31747009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO).
    Padovan M; Eoli M; Pellerino A; Rizzato S; Caserta C; Simonelli M; Michiara M; Caccese M; Anghileri E; Cerretti G; Rudà R; Zagonel V; Lombardi G
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34204877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
    Farooq AV; Degli Esposti S; Popat R; Thulasi P; Lonial S; Nooka AK; Jakubowiak A; Sborov D; Zaugg BE; Badros AZ; Jeng BH; Callander NS; Opalinska J; Baron J; Piontek T; Byrne J; Gupta I; Colby K
    Ophthalmol Ther; 2020 Dec; 9(4):889-911. PubMed ID: 32712806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.